Sign in
CompletedPhase 4

Applying Best Clinical Practices to Patients at High Risk of Respiratory Complications

Key facts

Who runs it
University of California, Los Angeles
Where
Los Angeles, United StatesSee the site
Trial code
Status
Completed
Phase
Phase 4
People taking part
12,248 people enrolled
Started
18 Feb 2022
Ended
7 May 2025
Type of study
Interventional
Treatments tested
  • Sugammadex 100 MG/ML [Bridion]
Record updated
29 July 2025

Who can take part

Age
18 years and older
Sex
Women and men
Healthy volunteers
Cannot take part
Show the full registry criteria (8)Hide the full registry criteria

Who can take part

  • UCLA Ronald Reagan or Santa Monica patients aged 18 and older who had a general anesthetic with either rocuronium or vecuronium
  • Patients who receive sugammadex from the specified study supply

Who cannot take part

  • Patients who remain intubated after surgery or leave the operating room with a tracheostomy in-situ
  • Patients with known hypersensitivity to any of the following: rocuronium, vecuronium, sugammadex, neostigmine or glycopyrrolate
  • Patients with known neuromuscular disease
  • Patients under the age of 18
  • Patients with a preoperative glomerular filtration rate less than 30 or on hemodialysis
  • Patients who did not receive reversal of neuromuscular blockade (with neostigmine in the pre-period or sugammadex in the post-period)

Where in United States

  • Ronald Reagan UCLA Medical CenterLos Angeles, United States

About the trial

What the trial wants to find out

The purpose of this study is to:

Read full original descriptionShow less

1. Perform a retrospective analysis on data contained in the UCLA Perioperative Data Warehouse on the incidence of respiratory dysfunction in the post-operative care unit (PACU) before and after the introduction of sugammadex into clinical practice. 2. Develop and implement a clinical best practice pathway designed to prevent postoperative respiratory complications in higher risk patients (such as those with OSA or preexisting respiratory disease) using education and clinical decision support in patients.

The group in the trial

  • CDS pathwayTreatment being tested

    When the anesthesiologist completes the preoperative evaluation for a patient who is flagged as having either respiratory disease or OSA and will receive general anesthesia, the anesthesiologist will receive a pop-up window reminding them of the best practice guidelines for pulmonary management in high-risk patients. We anticipate that the pathway will suggest 1) use of sugammadex to reverse neuromuscular blockade if rocuronium was used 2) use of objective train of four monitoring throughout the case and to confirm reversal 3) use of a tidal volume of 6-8 cc/kg 4) use of at least 5 cmH2O of PEEP

    Treatment: Sugammadex 100 MG/ML [Bridion]

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
A Prospective Digital Quality Improvement Project to Apply Best Clinical Practices to Patients at High Risk of Respiratory Complications
Record updated
29 July 2025